This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prevalence of Malnutrition in Oncology (PreMiO) (PreMiO)

This study has been completed.
Information provided by (Responsible Party):
Maurizio Muscaritoli, University of Roma La Sapienza Identifier:
First received: June 11, 2012
Last updated: December 1, 2015
Last verified: December 2015

It is estimated that up to 30% of cancer patients die because of the effects of malnutrition, caused by a discrepancy between nutritional needs and intake (or utilization) of energy and essential nutrients. Malnutrition and its severe complication, cancer cachexia, are negative prognostic factors in neoplastic patients, inducing Decreased response and tolerance to antineoplastic treatments, decline in the functional status, reduced quality of life and reduced survival. Prevalence data on malnutrition in italian oncology patients are lacking and the available literature data on weight loss and malnutrition in oncology refer to patients in different phases of disease and therapy. Most importantly , strategies for prevention of malnutrition and cachexia in oncology are still largely disregarded and scarcely implemented.

The main objective of this project is to assess the prevalence of malnutrition in patients undergoing first medical oncology visit in Italy. Secondary objective is to increase awareness of metabolic and nutritional issues among medical oncologists, thus favoring the inclusion of metabolic-nutritional screening and monitoring in medical oncology protocols. This would in turn contribute to reduce the negative consequences of malnutrition- and cachexia-related complications.

Malnutrition Pre-cachexia Cancer

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: The PreMiO Study: The Prevalence of Malnutrition in Oncology.

Resource links provided by NLM:

Further study details as provided by Maurizio Muscaritoli, University of Roma La Sapienza:

Primary Outcome Measures:
  • Malnutrition [ Time Frame: Assessed at the first medical oncology visit ]
    Malnutrition will be assessed by Mini Nutritional Assessment, biochemical analysis and diagnostic criteria of pre-cachexia.

Secondary Outcome Measures:
  • Anorexia [ Time Frame: Assessed at the first medical oncology visit ]
    Anorexia will be assessed via a modified version of AC/S-12 FAACT, via Visual Analogue Scale and specific questionnaire.

Enrollment: 1978
Study Start Date: June 2012
Study Completion Date: March 2015
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Cancer patients undergoing first medical oncology visit.

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Enrollment will be conducted at Italian ESMO-accredited centers and in other medical oncological centers in Italy. Six-thousand patients have been considered an adequate sample for a suitable estimation of the prevalence of malnutrition in Italian cancer patients at first medical oncology visit. Patient recruitment will be ensured through enrollment by 60 centers throughout the Italian national territory (North, Center, South and Islands).

Inclusion Criteria:

  • patients at first medical oncology visit
  • diagnosis of solid tumor
  • age > 18 years
  • no previous anticancer therapies (e.g. radiotherapy or chemotherapy)
  • Life expectancy >3 months according with PaP score
  • Informed consent

Exclusion Criteria:

  • Oral feeding incapacity or intestinal obstruction
  • Decompensated metabolic disorders
  • Severe liver failure (total bilirubin >1.5 mg/dL (25μmol/L), and AST (SGOT)/ ALT (SGPT) >2 x ULN or, in the case of metastatic liver, > 5 x ULN) or severe kidney failure (creatinine > 2.0 mg/dL (177 μmol/L), creatinine clearance ClCr < 50ml/min).
  • Acute Decompensated heart failure
  • Active infection
  • Primary brain tumors or metastatic brain tumors
  • severe psychiatric disorders
  • MMSE < 25/30 (in patient aged >70).
  • Inadequate logistical support for the study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01622036

Sapienza University of Rome
Rome, Italy, 00185
Sponsors and Collaborators
University of Roma La Sapienza
  More Information


Responsible Party: Maurizio Muscaritoli, MD, Associated Professor, University of Roma La Sapienza Identifier: NCT01622036     History of Changes
Other Study ID Numbers: MM-SL-PreMIO
Study First Received: June 11, 2012
Last Updated: December 1, 2015

Keywords provided by Maurizio Muscaritoli, University of Roma La Sapienza:
weight loss

Additional relevant MeSH terms:
Wasting Syndrome
Nutrition Disorders
Weight Loss
Body Weight Changes
Body Weight
Signs and Symptoms
Metabolic Diseases processed this record on September 19, 2017